AnaptysBio reports FY2026 net income $176.4M; Jemperli sales up 34% YoY

ANAPTYSBIO, INC

Jemperli global net sales $644M (£480M) for six months ended Jun 30, 2026, +34% YoY; Q2 $331M, +26% YoY.
FDA PDUFA Feb 2027 for Jemperli in dMMR/MSI-H rectal cancer; AZUR-1 interim results met primary cCR12 endpoint.
GSK/Tesaro litigation: trial held Jul 14-17; post-trial hearing Oct 20; judgement expected Q4 2026/Q1 2027, seeking Jemperli reversion.
Cash $164.1M at Jun 30, 2026 vs $211.6M at Dec 31, 2025; collaboration revenue $53.0M for six months.
Net income from continuing ops $176.4M ($6.09 diluted EPS) for six months; $181.5M tax benefit from valuation allowance release.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.